Saltar ao contenido
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avanzado
  • Spliceosome mutations are comm...
  • Citar
  • Text this
  • Enviar este rexistro por email
  • Imprimir
  • Exportar rexistro
    • Exportar a RefWorks
    • Exportar a EndNoteWeb
    • Exportar a EndNote
  • Permanent link
Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Spliceosome mutations are common in MPN-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide

Detalles Bibliográficos
Main Authors: Chowdhury, O, O'Sullivan, J, Barkas, N, Buck, G, Hamblin, A, Tefferi, A, Al-Ali, H, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A, Zhou, D, McMullin, M, Reiser, D, Zhong, J, Gale, R, Mead, A
Formato: Conference item
Publicado: American Society of Hematology 2018
  • Existencias
  • Descripción
  • Títulos similares
  • Staff View

Títulos similares

  • Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
    por: Chowdhury, O, et al.
    Publicado: (2020)
  • Profile of pomalidomide and its potential in the treatment of myelofibrosis
    por: Gowin KL, et al.
    Publicado: (2015-04-01)
  • The UK Myeloproliferative Neoplasm Registry for Myelofibrosis (UK-MPN-MF registry)
    por: Butt, N, et al.
    Publicado: (2019)
  • Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
    por: Alessandra Carobbio, et al.
    Publicado: (2023-07-01)
  • P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
    por: J.-J. Kiladjian, et al.
    Publicado: (2022-06-01)

Opciones de procura

  • Historial de Procuras
  • Procura avanzada

Buscar Máis

  • Revisar o catálogo
  • Lista alfabética
  • Explore Channels
  • Reservas de curso
  • Novos exemplares

Necesita Axuda?

  • Consello de procura
  • Consulte a un Bibliotecario
  • Preguntas Frecuentes